Rosen Law Firm Investigates Securities Claims Against Immutep Ltd.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy IMMP?
Source: PRnewswire
- Securities Claims Investigation: The Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ:IMMP) for allegedly issuing materially misleading business information, indicating significant legal risks that could adversely affect the company's stock price and investor confidence.
- Stock Price Plunge: On March 13, 2026, Immutep's American Depositary Receipt (ADR) price fell by $2.28, or 82.6%, closing at $0.48 after the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III study, reflecting extreme market pessimism regarding the company's future prospects.
- Class Action Preparation: The Rosen Law Firm is preparing a class action to seek compensation for investor losses, with no out-of-pocket fees required, which may attract more affected shareholders to participate and increase legal pressure on Immutep.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its strong track record and expertise in securities litigation, potentially enhancing investor trust and willingness to engage in the class action.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMMP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMMP
Wall Street analysts forecast IMMP stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.321
Low
12.00
Averages
12.00
High
12.00
Current: 0.321
Low
12.00
Averages
12.00
High
12.00
About IMMP
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rosen Law Firm Investigates Immutep Securities Claims
- Securities Claims Investigation: The Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Immutep Ltd. (NASDAQ: IMMP) due to allegations of materially misleading business information, which may have led to significant investor losses.
- Class Action Preparation: Shareholders who purchased Immutep securities may be entitled to compensation without any out-of-pocket fees, as the Rosen Law Firm prepares a class action to recover investor losses.
- Trial Discontinuation Announcement: On March 13, 2026, Immutep announced the discontinuation of its TACTI-004 Phase III study based on the Independent Data Monitoring Committee's recommendation following a planned interim futility analysis, indicating that the trial was deemed ineffective.
- Stock Price Plummet: Following this announcement, Immutep's American Depositary Receipt (ADR) price fell by $2.28, or 82.6%, closing at $0.48 per ADR, reflecting extreme market pessimism regarding the company's future prospects.
See More
Rosen Law Firm Investigates Securities Claims Against Immutep Ltd.
- Securities Claims Investigation: The Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ:IMMP) for allegedly issuing materially misleading business information, indicating significant legal risks that could adversely affect the company's stock price and investor confidence.
- Stock Price Plunge: On March 13, 2026, Immutep's American Depositary Receipt (ADR) price fell by $2.28, or 82.6%, closing at $0.48 after the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III study, reflecting extreme market pessimism regarding the company's future prospects.
- Class Action Preparation: The Rosen Law Firm is preparing a class action to seek compensation for investor losses, with no out-of-pocket fees required, which may attract more affected shareholders to participate and increase legal pressure on Immutep.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its strong track record and expertise in securities litigation, potentially enhancing investor trust and willingness to engage in the class action.
See More
Investigation Launched into Immutep for Securities Fraud Claims
- Investigation Initiated: Pomerantz LLP is investigating Immutep Limited for potential securities fraud or unlawful business practices, which could lead to significant losses for investors.
- Trial Discontinuation: On March 13, 2026, Immutep announced the discontinuation of its TACTI-004 Phase III study based on the Independent Data Monitoring Committee's recommendation, indicating the drug's ineffectiveness in non-small cell lung cancer patients, resulting in a major trust crisis for the company.
- Stock Price Plunge: Following the trial termination announcement, Immutep's American Depositary Receipt (ADR) price plummeted by 82.44%, from $2.27 to $0.48, reflecting extreme market pessimism regarding the company's future prospects.
- Legal Implications: The investigation may lead to class action lawsuits against Immutep, further exacerbating its financial and reputational risks, prompting investors to closely monitor developments to safeguard their interests.
See More
Investigation of Securities Claims Against Immutep Ltd.
- Securities Claims Investigation: The Rosen Law Firm is investigating potential securities claims on behalf of Immutep Ltd. shareholders due to allegations of materially misleading business information, which may have led to significant investor losses.
- Stock Price Plunge: Following the announcement on March 13, 2026, regarding the discontinuation of the TACTI-004 Phase III study based on futility analysis, Immutep's ADR price fell by $2.28, or 82.6%, closing at $0.48, severely impacting investor confidence.
- Class Action Preparation: The Rosen Law Firm is preparing a class action to recover investor losses, allowing shareholders to participate without upfront fees through a contingency fee arrangement, thus minimizing their financial risk.
- Firm's Credentials: The Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its expertise and success in the field, which enhances investor trust in their representation.
See More
Rosen Law Firm Investigates Immutep Securities Claims
- Securities Claims Investigation: The Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ:IMMP) due to allegations of materially misleading business information, highlighting significant risks in the company's information disclosure practices.
- Clinical Trial Discontinuation: On March 13, 2026, Immutep announced the discontinuation of the TACTI 004 Phase III study based on recommendations from the Independent Data Monitoring Committee, leading to a substantial decline in investor confidence regarding the company's future prospects.
- Stock Price Plunge: Following the announcement of the trial's discontinuation, Immutep's American Depositary Receipt (ADR) price fell by $2.28, or 82.6%, closing at $0.48, reflecting extreme pessimism in the market about the company's outlook.
- Class Action Preparation: The Rosen Law Firm is preparing a class action lawsuit, allowing investors to seek compensation without any out-of-pocket costs, underscoring the importance of legal support for investor rights and the need for accountability.
See More
Immutep Faces Securities Claims Investigation
- Securities Claims Investigation: The Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ: IMMP) for possibly issuing materially misleading business information, indicating significant risks in the company's information disclosure practices.
- Stock Price Plunge: On March 13, 2026, Immutep's ADR price fell by $2.28, or 82.6%, after the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III study, reflecting extreme market pessimism regarding the company's future prospects.
- Class Action Preparation: The Rosen Law Firm is preparing a class action against Immutep, allowing investors to seek compensation without any out-of-pocket fees, suggesting that the legal risks faced by the company could have profound implications for its financial health.
- Law Firm's Expertise: The Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its professional capability and influence in handling such cases.
See More
Rosen Law Firm Investigates Immutep Securities Claims
- Securities Claims Investigation: The Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Immutep Ltd. (NASDAQ: IMMP) due to allegations of materially misleading business information, which may have led to significant investor losses.
- Class Action Preparation: Shareholders who purchased Immutep securities may be entitled to compensation without any out-of-pocket fees, as the Rosen Law Firm prepares a class action to recover investor losses.
- Trial Discontinuation Announcement: On March 13, 2026, Immutep announced the discontinuation of its TACTI-004 Phase III study based on the Independent Data Monitoring Committee's recommendation following a planned interim futility analysis, indicating that the trial was deemed ineffective.
- Stock Price Plummet: Following this announcement, Immutep's American Depositary Receipt (ADR) price fell by $2.28, or 82.6%, closing at $0.48 per ADR, reflecting extreme market pessimism regarding the company's future prospects.
See More
Rosen Law Firm Investigates Securities Claims Against Immutep Ltd.
- Securities Claims Investigation: The Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ:IMMP) for allegedly issuing materially misleading business information, indicating significant legal risks that could adversely affect the company's stock price and investor confidence.
- Stock Price Plunge: On March 13, 2026, Immutep's American Depositary Receipt (ADR) price fell by $2.28, or 82.6%, closing at $0.48 after the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III study, reflecting extreme market pessimism regarding the company's future prospects.
- Class Action Preparation: The Rosen Law Firm is preparing a class action to seek compensation for investor losses, with no out-of-pocket fees required, which may attract more affected shareholders to participate and increase legal pressure on Immutep.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its strong track record and expertise in securities litigation, potentially enhancing investor trust and willingness to engage in the class action.
See More
Investigation Launched into Immutep for Securities Fraud Claims
- Investigation Initiated: Pomerantz LLP is investigating Immutep Limited for potential securities fraud or unlawful business practices, which could lead to significant losses for investors.
- Trial Discontinuation: On March 13, 2026, Immutep announced the discontinuation of its TACTI-004 Phase III study based on the Independent Data Monitoring Committee's recommendation, indicating the drug's ineffectiveness in non-small cell lung cancer patients, resulting in a major trust crisis for the company.
- Stock Price Plunge: Following the trial termination announcement, Immutep's American Depositary Receipt (ADR) price plummeted by 82.44%, from $2.27 to $0.48, reflecting extreme market pessimism regarding the company's future prospects.
- Legal Implications: The investigation may lead to class action lawsuits against Immutep, further exacerbating its financial and reputational risks, prompting investors to closely monitor developments to safeguard their interests.
See More
Investigation of Securities Claims Against Immutep Ltd.
- Securities Claims Investigation: The Rosen Law Firm is investigating potential securities claims on behalf of Immutep Ltd. shareholders due to allegations of materially misleading business information, which may have led to significant investor losses.
- Stock Price Plunge: Following the announcement on March 13, 2026, regarding the discontinuation of the TACTI-004 Phase III study based on futility analysis, Immutep's ADR price fell by $2.28, or 82.6%, closing at $0.48, severely impacting investor confidence.
- Class Action Preparation: The Rosen Law Firm is preparing a class action to recover investor losses, allowing shareholders to participate without upfront fees through a contingency fee arrangement, thus minimizing their financial risk.
- Firm's Credentials: The Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its expertise and success in the field, which enhances investor trust in their representation.
See More
Rosen Law Firm Investigates Immutep Securities Claims
- Securities Claims Investigation: The Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ:IMMP) due to allegations of materially misleading business information, highlighting significant risks in the company's information disclosure practices.
- Clinical Trial Discontinuation: On March 13, 2026, Immutep announced the discontinuation of the TACTI 004 Phase III study based on recommendations from the Independent Data Monitoring Committee, leading to a substantial decline in investor confidence regarding the company's future prospects.
- Stock Price Plunge: Following the announcement of the trial's discontinuation, Immutep's American Depositary Receipt (ADR) price fell by $2.28, or 82.6%, closing at $0.48, reflecting extreme pessimism in the market about the company's outlook.
- Class Action Preparation: The Rosen Law Firm is preparing a class action lawsuit, allowing investors to seek compensation without any out-of-pocket costs, underscoring the importance of legal support for investor rights and the need for accountability.
See More
Immutep Faces Securities Claims Investigation
- Securities Claims Investigation: The Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ: IMMP) for possibly issuing materially misleading business information, indicating significant risks in the company's information disclosure practices.
- Stock Price Plunge: On March 13, 2026, Immutep's ADR price fell by $2.28, or 82.6%, after the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III study, reflecting extreme market pessimism regarding the company's future prospects.
- Class Action Preparation: The Rosen Law Firm is preparing a class action against Immutep, allowing investors to seek compensation without any out-of-pocket fees, suggesting that the legal risks faced by the company could have profound implications for its financial health.
- Law Firm's Expertise: The Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its professional capability and influence in handling such cases.
See More
